TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.